1Division of Nephrology, Department of Medicine, UCLA School of Medicine, Los Angeles, CA, USA.
Recombinant human erythropoietin (rHuEPO) therapy significantly improves survival and quality of life for patients with chronic renal failure anemia. Further research is needed to address resistance, iron deficiency, and optimal treatment strategies.
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: